The medication vibegron led to improvements in symptoms of overactive bladder and overall quality of life in men undergoing treatment for benign prostatic hyperplasia, according to findings from a ...

In the United States, the prevalence of overactive bladder (OAB) among men was 14.5% in 2015 to 2020, reflecting a significant increase from 2005, according to a study published online July 15 in ...

In a recent study published in the journal Scientific Reports, researchers in China examined the trends and prevalence of overactive bladder (OAB) among adult men in the United States of America (US) ...

Chinese investigators evaluated 15 years' worth of data from more than 18,000 adult men in the U.S. to better characterize OAB and its risk factors. The overall presence of OAB increased significantly ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic ...

Please provide your email address to receive an email when new articles are posted on . The proportion of men with overactive bladder increased significantly from 2015 to 2020. Results showed ...

A study of NHANES 2005-2020 data found that the prevalence of overactive bladder among men in the US increased significantly from 11.7% in 2009-2014 to 14.5% in 2015-2020. Overactive bladder (OAB) ...

Men with overactive bladder had significant 95% reduced odds of urinary tract cancers compared with a reference group of men with urolithiasis, after adjusting for age. Overactive bladder (OAB) is ...

Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new data from its urology and oncology portfolios at the American Urological Association (AUA) 2026 Annual Meeting, held on May ...

One in six adults have bladder control problems. It can disrupt sleep or cause accidents, lead to social isolation and depression and affects women more than men. Overactive bladder syndrome affects ...